Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Denali Advisors LLC

Denali Advisors LLC trimmed its position in Hologic, Inc. (NASDAQ:HOLX) by 29.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,700 shares of the medical equipment provider’s stock after selling 2,000 shares during the period. Denali Advisors LLC’s holdings in Hologic were worth $366,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. McGlone Suttner Wealth Management Inc. purchased a new position in shares of Hologic during the fourth quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV lifted its stake in shares of Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 227 shares during the period. Allworth Financial LP boosted its holdings in shares of Hologic by 39.3% during the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 179 shares during the last quarter. Mather Group LLC. purchased a new stake in shares of Hologic in the first quarter valued at $48,000. Finally, Livforsakringsbolaget Skandia Omsesidigt increased its stake in Hologic by 145.3% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 468 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

NASDAQ:HOLX opened at $73.48 on Thursday. The firm’s fifty day simple moving average is $74.14 and its 200 day simple moving average is $74.36. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $82.45. The firm has a market capitalization of $17.15 billion, a price-to-earnings ratio of 37.49, a PEG ratio of 2.45 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the previous year, the firm posted $1.06 earnings per share. The firm’s quarterly revenue was down .8% on a year-over-year basis. As a group, equities research analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on HOLX shares. Argus raised their price target on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Friday, May 3rd. Stephens started coverage on shares of Hologic in a research report on Thursday, June 27th. They set an “overweight” rating and a $87.00 price target for the company. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Finally, Evercore ISI dropped their price objective on Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a report on Tuesday. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average target price of $85.55.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.